Biotech CEOs often stress to their investors that they are focused on a specific technology or therapy area – the last thing they really want to be, but the sort of thing that investors like to hear. But there is a true dilemma here for biotech CEOs: should they persist with a focused development model, or spread risk by adopting a diverse project portfolio, or, at the very least, a dual business model?